angiotensin ii has been researched along with lovastatin in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Choi, KH; Han, DS; Kang, BS; Kang, SW; Lee, HY; Lee, SW | 1 |
| Altieri, PI; Castro, M; Escobales, N; Sanabria, P | 1 |
| Haneda, T; Kashiwagi, Y; Kawabe, J; Kikuchi, K; Nakamura, Y; Oi, S; Osaki, J | 1 |
| Kolina, IB; Neverov, NI; Shilov, EM; Shvetsov, MIu; Stavrovskaia, EV; Zakharova, EV | 1 |
| Altieri, PI; Crespo, MJ; Escobales, N; Furilla, RA | 1 |
| Dokmeci, MR; Ferreira, L; Khademhosseini, A; Leijten, J; Miscuglio, M; Nissan, X; Pitrez, PR; Ribas, J; Rouwkema, J; Zhang, YS | 1 |
| Chen, Z; Duan, Q; Gong, L; Liu, Z; Wu, P; Xia, F; Yang, T; Zhao, T; Zheng, Z | 1 |
8 other study(ies) available for angiotensin ii and lovastatin
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
The effect of lovastatin on proliferation of cultured rat mesangial and aortic smooth muscle cells.
Topics: Angiotensin II; Animals; Aorta; Cell Division; Cells, Cultured; Endothelins; Glomerular Mesangium; Lovastatin; Male; Muscle, Smooth, Vascular; Platelet-Derived Growth Factor; Rats; Rats, Sprague-Dawley; Thymidine | 1995 |
Simvastatin releases Ca2+ from a thapsigargin-sensitive pool and inhibits InsP3-dependent Ca2+ mobilization in vascular smooth muscle cells.
Topics: Angiotensin II; Animals; Calcium; Calcium-Transporting ATPases; Cells, Cultured; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inositol 1,4,5-Trisphosphate; Lovastatin; Muscle, Smooth, Vascular; Rats; Simvastatin; Thapsigargin | 1996 |
Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells.
Topics: Angiotensin II; Animals; Animals, Newborn; Calcium-Calmodulin-Dependent Protein Kinases; Cardiomegaly; Cell Division; Cell Membrane; Cells, Cultured; DNA; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Myocardium; Naphthalenes; Pravastatin; Proto-Oncogene Proteins p21(ras); Rats; Rats, Sprague-Dawley; RNA; Simvastatin | 1999 |
[Effects of pathogenetic therapy on blood cholesterol in patients with glomerulonephritis].
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Anticholesteremic Agents; Antihypertensive Agents; Azathioprine; Captopril; Cholesterol; Creatinine; Cyclophosphamide; Data Interpretation, Statistical; Enalapril; Female; Glomerulonephritis; Humans; Immunosuppressive Agents; Lovastatin; Male; Nephrotic Syndrome; Prednisolone; Retrospective Studies; Tetrazoles; Time Factors; Valine; Valsartan | 2001 |
Inhibition of smooth muscle cell calcium mobilization and aortic ring contraction by lactone vastatins.
Topics: Angiogenesis Inhibitors; Angiotensin II; Animals; Aorta, Thoracic; Calcium; Collagen Type VIII; Dose-Response Relationship, Drug; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Lovastatin; Male; Models, Cardiovascular; Muscle Contraction; Muscle, Smooth, Vascular; Norepinephrine; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin; Vasoconstrictor Agents | 1996 |
Biomechanical Strain Exacerbates Inflammation on a Progeria-on-a-Chip Model.
Topics: Angiotensin II; Biomechanical Phenomena; Blood Vessels; Cytoskeleton; Disease Progression; Humans; Induced Pluripotent Stem Cells; Inflammation; Lab-On-A-Chip Devices; Lovastatin; Microfluidics; Myocytes, Smooth Muscle; Phenotype; Progeria | 2017 |
Lovastatin attenuates angiotensin II induced cardiovascular fibrosis through the suppression of YAP/TAZ signaling.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Animals; Anticholesteremic Agents; Cardiovascular Diseases; Cell Cycle Proteins; Cell Line; Fibrosis; Lovastatin; Male; Mice, Inbred C57BL; Myocardium; Signal Transduction; Trans-Activators; YAP-Signaling Proteins | 2019 |